Compare Simon Property Group Inc (SPG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs BIO-TECHNE Corp — how do they compare? Simon Property Group Inc trades at $199.6 (market cap $64.59B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Simon Property Group Inc is far larger — about 5.7× BIO-TECHNE Corp's market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Simon Property Group Inc for 99 Days and BIO-TECHNE Corp for 63 Days on average.
| SPG | TECH | |
|---|---|---|
Market Cap | $64.59B | $11.36B |
Volume | 1,093,907 | 5,390,331 |
Sector | Real Estate | Health |
52-Week High | $236.70 | $72.61 |
52-Week Low | $173.35 | $43.31 |
Typical Hold Time | 99 Days | 63 Days |
Enterprise Value | $93.03B | $11.39B |
Dividend Yield | 4.46% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPG trades at $197.59, down 2.06% amid bearish technical signals, though fundamentals show strength with Q4 2025 EPS beating estimates at $9.35 versus $1.90 expected. The company maintains robust profitability with 66.57% net income margin and 135.7% ROE, while recent news highlights strong leasing demand and a new media network launch to monetize mall traffic.
Outlook is mixed: analyst consensus targets $222.90 (12.8% upside) with 42% buy ratings, but technical indicators signal caution. Key risks include $24.21B long-term debt and sensitivity to interest rates, though A-rated balance sheet and dividend yield near 4.5% offer support. Revenue growth to $6.9B in 2026 suggests stability.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
